ARS Results, Milestones, Progress Update

 

• Financial Position: Ended the year with $228.4 million in cash, cash equivalents, and short-term investments.

• R&D Expenses: Research and development expenses increased to $20.3 million for the year, up from $18.4 million in 2022.

• G&A Expenses: General and administrative expenses rose to $47.3 million for the year, a significant increase from $18.5 million in the previous year.

• Net Loss: Reported a net loss of $54.4 million for the year, compared to a net loss of $34.7 million in 2022.

• Regulatory Milestones: Preparing to submit response to the FDA's CRL for neffy in early Q2 2024, with a potential launch in the second half of the year.

• Clinical Advancements: Positive clinical data from Phase 2 trial in chronic spontaneous urticaria, meeting primary endpoints.

https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-reports-213328147.html